[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fY9lWBlceaJMk_M-8CZZEr1ibgN62Y14GZQ5iL6rlvI4":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":34,"phaseBuckets":60,"rows":67},"Parc de Salut Mar",[4],179,false,27,4,66374,9,132,[14,17,19,22,25,27,29,32],{"name":15,"count":16},"Healthy Volunteers",13,{"name":18,"count":11},"Healthy",{"name":20,"count":21},"Psychological Trauma",8,{"name":23,"count":24},"Colonic Diseases",5,{"name":26,"count":24},"Heart Failure",{"name":28,"count":9},"Down Syndrome",{"name":30,"count":31},"Lung Cancer",3,{"name":33,"count":31},"Ankyloglossia",[35,40,45,50,55],{"nctId":36,"briefTitle":37,"date":38,"intervention":39},"NCT04480242","Asthma Research in Children and Adolescents","2025-10-31","Inhaled Corticosteroids",{"nctId":41,"briefTitle":42,"date":43,"intervention":44},"NCT05780229","Effectiveness of Treatments for Massive Rotator Cuff Tears: Mixed Methodology.","2025-12-31","Pain-Relief Medication",{"nctId":46,"briefTitle":47,"date":48,"intervention":49},"NCT06952452","Pharmacogenomics of antiVEGF in Patients With Age-Associated Macular Degeneration (AMD)","2026-07","Bevacizumab",{"nctId":51,"briefTitle":52,"date":53,"intervention":54},"NCT06606067","Duloxetine to Prevent Chronic Postsurgical Pain After Inguinal Hernia Repair in Patients at High Risk","2026-07-31","Duloxetine",{"nctId":56,"briefTitle":57,"date":58,"intervention":59},"NCT06258850","REstoration of VItamin D in Pulmonary Arterial Hypertension","2027-06","Calcifediol Oral",[61,62,63,64,65,66],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[68,94,117,140,158,181,208,226,244,262,291,309,334,352,379,404,431,449,473,499,528,556,574,599,617,644,662,699,724,742,765,788,813,836,860,884,910,928,946,971,989,1014,1032,1057,1075,1098,1116,1134,1152,1175,1201,1219,1237,1255,1282,1300,1318,1336,1354,1380,1404,1427,1450,1473,1500,1518,1544,1570,1595,1622,1647,1680,1698,1716,1734,1752,1770,1788,1814],{"intervention":59,"totalTrials":69,"cells":70},1,{"EARLY_PHASE1":71,"PHASE1":74,"PHASE2":76,"PHASE3":78,"PHASE4":80,"NA":92},{"trials":72,"activeCount":73},[],0,{"trials":75,"activeCount":73},[],{"trials":77,"activeCount":73},[],{"trials":79,"activeCount":73},[],{"trials":81,"activeCount":69,"soonestReadout":58},[82],{"nctId":56,"briefTitle":57,"status":83,"phases":84,"primaryCompletion":58,"completion":85,"start":86,"enrollment":87,"conditions":88,"interventions":91},"NOT_YET_RECRUITING",[65],"2027-12","2024-07-01",102,[89,90],"Pulmonary Artery Hypertension","Vitamin d Deficiency",[59],{"trials":93,"activeCount":73},[],{"intervention":54,"totalTrials":69,"cells":95},{"EARLY_PHASE1":96,"PHASE1":98,"PHASE2":100,"PHASE3":102,"PHASE4":113,"NA":115},{"trials":97,"activeCount":73},[],{"trials":99,"activeCount":73},[],{"trials":101,"activeCount":73},[],{"trials":103,"activeCount":69,"soonestReadout":53},[104],{"nctId":51,"briefTitle":52,"status":105,"phases":106,"primaryCompletion":53,"completion":107,"start":108,"enrollment":109,"conditions":110,"interventions":112},"ACTIVE_NOT_RECRUITING",[64],"2026-12-31","2024-09-03",294,[111],"Chronic Post-surgical Pain",[54],{"trials":114,"activeCount":73},[],{"trials":116,"activeCount":73},[],{"intervention":49,"totalTrials":69,"cells":118},{"EARLY_PHASE1":119,"PHASE1":121,"PHASE2":123,"PHASE3":125,"PHASE4":136,"NA":138},{"trials":120,"activeCount":73},[],{"trials":122,"activeCount":73},[],{"trials":124,"activeCount":73},[],{"trials":126,"activeCount":69,"soonestReadout":48},[127],{"nctId":46,"briefTitle":47,"status":128,"phases":129,"primaryCompletion":48,"completion":48,"start":130,"enrollment":131,"conditions":132,"interventions":134},"RECRUITING",[64],"2022-11-18",630,[133],"Wet Age-related Macular Degeneration",[49,135],"Ranibizumab Ophthalmic",{"trials":137,"activeCount":73},[],{"trials":139,"activeCount":73},[],{"intervention":135,"totalTrials":69,"cells":141},{"EARLY_PHASE1":142,"PHASE1":144,"PHASE2":146,"PHASE3":148,"PHASE4":154,"NA":156},{"trials":143,"activeCount":73},[],{"trials":145,"activeCount":73},[],{"trials":147,"activeCount":73},[],{"trials":149,"activeCount":69,"soonestReadout":48},[150],{"nctId":46,"briefTitle":47,"status":128,"phases":151,"primaryCompletion":48,"completion":48,"start":130,"enrollment":131,"conditions":152,"interventions":153},[64],[133],[49,135],{"trials":155,"activeCount":73},[],{"trials":157,"activeCount":73},[],{"intervention":44,"totalTrials":69,"cells":159},{"EARLY_PHASE1":160,"PHASE1":162,"PHASE2":164,"PHASE3":166,"PHASE4":168,"NA":170},{"trials":161,"activeCount":73},[],{"trials":163,"activeCount":73},[],{"trials":165,"activeCount":73},[],{"trials":167,"activeCount":73},[],{"trials":169,"activeCount":73},[],{"trials":171,"activeCount":69,"soonestReadout":43},[172],{"nctId":41,"briefTitle":42,"status":105,"phases":173,"primaryCompletion":43,"completion":174,"start":175,"enrollment":176,"conditions":177,"interventions":180},[],"2027-12-31","2019-03-27",200,[178,179],"Massive Rotator Cuff Tears","Shoulder Disease",[44],{"intervention":39,"totalTrials":69,"cells":182},{"EARLY_PHASE1":183,"PHASE1":185,"PHASE2":187,"PHASE3":189,"PHASE4":191,"NA":193},{"trials":184,"activeCount":73},[],{"trials":186,"activeCount":73},[],{"trials":188,"activeCount":73},[],{"trials":190,"activeCount":73},[],{"trials":192,"activeCount":73},[],{"trials":194,"activeCount":69,"soonestReadout":38},[195],{"nctId":36,"briefTitle":37,"status":105,"phases":196,"primaryCompletion":38,"completion":197,"start":198,"enrollment":199,"conditions":200,"interventions":204},[],"2030-12-31","2017-07-26",525,[201,202,203],"Persistent Asthma","Asthma in Children","Asthma Exacerbation",[39,205,206,207],"Fixed-Dose Combination of Inhaled Corticosteroids and Long- Acting Beta-agonist","Other treatments","Inhaler device",{"intervention":205,"totalTrials":69,"cells":209},{"EARLY_PHASE1":210,"PHASE1":212,"PHASE2":214,"PHASE3":216,"PHASE4":218,"NA":220},{"trials":211,"activeCount":73},[],{"trials":213,"activeCount":73},[],{"trials":215,"activeCount":73},[],{"trials":217,"activeCount":73},[],{"trials":219,"activeCount":73},[],{"trials":221,"activeCount":69,"soonestReadout":38},[222],{"nctId":36,"briefTitle":37,"status":105,"phases":223,"primaryCompletion":38,"completion":197,"start":198,"enrollment":199,"conditions":224,"interventions":225},[],[201,202,203],[39,205,206,207],{"intervention":206,"totalTrials":69,"cells":227},{"EARLY_PHASE1":228,"PHASE1":230,"PHASE2":232,"PHASE3":234,"PHASE4":236,"NA":238},{"trials":229,"activeCount":73},[],{"trials":231,"activeCount":73},[],{"trials":233,"activeCount":73},[],{"trials":235,"activeCount":73},[],{"trials":237,"activeCount":73},[],{"trials":239,"activeCount":69,"soonestReadout":38},[240],{"nctId":36,"briefTitle":37,"status":105,"phases":241,"primaryCompletion":38,"completion":197,"start":198,"enrollment":199,"conditions":242,"interventions":243},[],[201,202,203],[39,205,206,207],{"intervention":207,"totalTrials":69,"cells":245},{"EARLY_PHASE1":246,"PHASE1":248,"PHASE2":250,"PHASE3":252,"PHASE4":254,"NA":256},{"trials":247,"activeCount":73},[],{"trials":249,"activeCount":73},[],{"trials":251,"activeCount":73},[],{"trials":253,"activeCount":73},[],{"trials":255,"activeCount":73},[],{"trials":257,"activeCount":69,"soonestReadout":38},[258],{"nctId":36,"briefTitle":37,"status":105,"phases":259,"primaryCompletion":38,"completion":197,"start":198,"enrollment":199,"conditions":260,"interventions":261},[],[201,202,203],[39,205,206,207],{"intervention":263,"totalTrials":69,"cells":264},"IncobotulinumtoxinA",{"EARLY_PHASE1":265,"PHASE1":267,"PHASE2":269,"PHASE3":271,"PHASE4":273,"NA":289},{"trials":266,"activeCount":73},[],{"trials":268,"activeCount":73},[],{"trials":270,"activeCount":73},[],{"trials":272,"activeCount":73},[],{"trials":274,"activeCount":73},[275],{"nctId":276,"briefTitle":277,"status":278,"phases":279,"primaryCompletion":280,"completion":281,"start":282,"enrollment":283,"conditions":284,"interventions":287},"NCT03044080","Effects of Botulinum Neurotoxin Type A (BoNT\u002FA) Free of Complexing Proteins in the Spastic Equinovarus Foot","COMPLETED",[65],"2017-06-30","2017-09-30","2015-01-01",20,[285,286],"Stroke Rehabilitation","Stroke Rehabilitation Spasticity Management",[263,288],"OnabotulinumtoxinA",{"trials":290,"activeCount":73},[],{"intervention":288,"totalTrials":69,"cells":292},{"EARLY_PHASE1":293,"PHASE1":295,"PHASE2":297,"PHASE3":299,"PHASE4":301,"NA":307},{"trials":294,"activeCount":73},[],{"trials":296,"activeCount":73},[],{"trials":298,"activeCount":73},[],{"trials":300,"activeCount":73},[],{"trials":302,"activeCount":73},[303],{"nctId":276,"briefTitle":277,"status":278,"phases":304,"primaryCompletion":280,"completion":281,"start":282,"enrollment":283,"conditions":305,"interventions":306},[65],[285,286],[263,288],{"trials":308,"activeCount":73},[],{"intervention":310,"totalTrials":69,"cells":311},"Polyethylene glycol + ascorbate",{"EARLY_PHASE1":312,"PHASE1":314,"PHASE2":316,"PHASE3":318,"PHASE4":320,"NA":332},{"trials":313,"activeCount":73},[],{"trials":315,"activeCount":73},[],{"trials":317,"activeCount":73},[],{"trials":319,"activeCount":73},[],{"trials":321,"activeCount":73},[322],{"nctId":323,"briefTitle":324,"status":278,"phases":325,"primaryCompletion":326,"completion":326,"start":327,"enrollment":328,"conditions":329,"interventions":330},"NCT04598880","Comparison of 1 Liter PEG With Ascorbate and Sodium Picosulfate \u002F Magnesium Citrate for High Quality Colon Cleansing",[65],"2024-04-01","2020-11-06",1180,[23],[310,331],"Sodium picosulfate + magnesium citrate",{"trials":333,"activeCount":73},[],{"intervention":331,"totalTrials":69,"cells":335},{"EARLY_PHASE1":336,"PHASE1":338,"PHASE2":340,"PHASE3":342,"PHASE4":344,"NA":350},{"trials":337,"activeCount":73},[],{"trials":339,"activeCount":73},[],{"trials":341,"activeCount":73},[],{"trials":343,"activeCount":73},[],{"trials":345,"activeCount":73},[346],{"nctId":323,"briefTitle":324,"status":278,"phases":347,"primaryCompletion":326,"completion":326,"start":327,"enrollment":328,"conditions":348,"interventions":349},[65],[23],[310,331],{"trials":351,"activeCount":73},[],{"intervention":353,"totalTrials":69,"cells":354},"Bupivacaine hydrochloride",{"EARLY_PHASE1":355,"PHASE1":357,"PHASE2":359,"PHASE3":361,"PHASE4":363,"NA":377},{"trials":356,"activeCount":73},[],{"trials":358,"activeCount":73},[],{"trials":360,"activeCount":73},[],{"trials":362,"activeCount":73},[],{"trials":364,"activeCount":73},[365],{"nctId":366,"briefTitle":367,"status":278,"phases":368,"primaryCompletion":369,"completion":370,"start":371,"enrollment":372,"conditions":373,"interventions":376},"NCT02630160","The Influence of Local Infiltration Analgesia by Catheter in Postoperative Control Pain After Total Hip Replacement",[65],"2014-05","2014-06","2013-03",100,[374,375],"Musculoskeletal Pain","Hip Injuries",[353],{"trials":378,"activeCount":73},[],{"intervention":380,"totalTrials":69,"cells":381},"FSH-r",{"EARLY_PHASE1":382,"PHASE1":384,"PHASE2":386,"PHASE3":388,"PHASE4":390,"NA":402},{"trials":383,"activeCount":73},[],{"trials":385,"activeCount":73},[],{"trials":387,"activeCount":73},[],{"trials":389,"activeCount":73},[],{"trials":391,"activeCount":73},[392],{"nctId":393,"briefTitle":394,"status":278,"phases":395,"primaryCompletion":396,"completion":396,"start":397,"enrollment":398,"conditions":399,"interventions":401},"NCT01376999","Step Up Versus Step Down in Controlled Ovarian Stimulation",[65],"2014-02","2010-04",158,[400],"No Explained Sterility",[380],{"trials":403,"activeCount":73},[],{"intervention":405,"totalTrials":69,"cells":406},"Oral strogen",{"EARLY_PHASE1":407,"PHASE1":409,"PHASE2":411,"PHASE3":413,"PHASE4":415,"NA":429},{"trials":408,"activeCount":73},[],{"trials":410,"activeCount":73},[],{"trials":412,"activeCount":73},[],{"trials":414,"activeCount":73},[],{"trials":416,"activeCount":73},[417],{"nctId":418,"briefTitle":419,"status":278,"phases":420,"primaryCompletion":421,"completion":422,"start":423,"enrollment":424,"conditions":425,"interventions":427},"NCT01430650","Endometrial Priming for Embryo Transfer",[65],"2014-10","2015-07","2010-07",140,[426],"Sterility",[405,428],"Transdermal strogen",{"trials":430,"activeCount":73},[],{"intervention":428,"totalTrials":69,"cells":432},{"EARLY_PHASE1":433,"PHASE1":435,"PHASE2":437,"PHASE3":439,"PHASE4":441,"NA":447},{"trials":434,"activeCount":73},[],{"trials":436,"activeCount":73},[],{"trials":438,"activeCount":73},[],{"trials":440,"activeCount":73},[],{"trials":442,"activeCount":73},[443],{"nctId":418,"briefTitle":419,"status":278,"phases":444,"primaryCompletion":421,"completion":422,"start":423,"enrollment":424,"conditions":445,"interventions":446},[65],[426],[405,428],{"trials":448,"activeCount":73},[],{"intervention":450,"totalTrials":69,"cells":451},"Levosimendan",{"EARLY_PHASE1":452,"PHASE1":454,"PHASE2":456,"PHASE3":458,"PHASE4":460,"NA":471},{"trials":453,"activeCount":73},[],{"trials":455,"activeCount":73},[],{"trials":457,"activeCount":73},[],{"trials":459,"activeCount":73},[],{"trials":461,"activeCount":73},[462],{"nctId":463,"briefTitle":464,"status":278,"phases":465,"primaryCompletion":466,"completion":467,"start":397,"enrollment":468,"conditions":469,"interventions":470},"NCT01536132","Intermittent Intravenous Levosimendan in Ambulatory Advanced Chronic Heart Failure Patients",[65],"2013-10","2015-11",70,[26],[450],{"trials":472,"activeCount":73},[],{"intervention":474,"totalTrials":69,"cells":475},"Pregabalin",{"EARLY_PHASE1":476,"PHASE1":478,"PHASE2":480,"PHASE3":482,"PHASE4":484,"NA":497},{"trials":477,"activeCount":73},[],{"trials":479,"activeCount":73},[],{"trials":481,"activeCount":73},[],{"trials":483,"activeCount":73},[],{"trials":485,"activeCount":73},[486],{"nctId":487,"briefTitle":488,"status":489,"phases":490,"primaryCompletion":491,"completion":491,"start":492,"enrollment":283,"conditions":493,"interventions":496},"NCT01768988","Efficacy Of Pregabalin In The Treatment Of Pancreatic Cancer Pain. A Randomized Controlled Double-Blind, Parallel Group Study","TERMINATED",[65],"2017-12","2012-08",[494,495],"Pancreatic Cancer","Visceral Pain",[474],{"trials":498,"activeCount":73},[],{"intervention":500,"totalTrials":69,"cells":501},"bisphosphonate",{"EARLY_PHASE1":502,"PHASE1":504,"PHASE2":506,"PHASE3":508,"PHASE4":510,"NA":526},{"trials":503,"activeCount":73},[],{"trials":505,"activeCount":73},[],{"trials":507,"activeCount":73},[],{"trials":509,"activeCount":73},[],{"trials":511,"activeCount":73},[512],{"nctId":513,"briefTitle":514,"status":515,"phases":516,"primaryCompletion":517,"completion":518,"start":519,"enrollment":520,"conditions":521,"interventions":525},"NCT03811509","Breast Cancer Women on Aromatase Inhibitors Treatment","UNKNOWN",[65],"2021-01-01","2022-12-31","2016-01-01",1000,[522,523,524],"Osteoporosis","Osteoporosis Fracture","Arthralgia Generalized",[500],{"trials":527,"activeCount":73},[],{"intervention":529,"totalTrials":69,"cells":530},"Ferric carboxymaltose",{"EARLY_PHASE1":531,"PHASE1":533,"PHASE2":535,"PHASE3":537,"PHASE4":539,"NA":554},{"trials":532,"activeCount":73},[],{"trials":534,"activeCount":73},[],{"trials":536,"activeCount":73},[],{"trials":538,"activeCount":73},[],{"trials":540,"activeCount":73},[541],{"nctId":542,"briefTitle":543,"status":278,"phases":544,"primaryCompletion":545,"completion":546,"start":547,"enrollment":548,"conditions":549,"interventions":552},"NCT01913808","Comparing Intravenous and Oral Iron in Postoperative Anemia",[65],"2012-02","2013-01","2011-01",122,[550,551],"Postoperative Anemia","Osteoarthritis, Knee",[529,553],"ferrous glycine sulphate",{"trials":555,"activeCount":73},[],{"intervention":553,"totalTrials":69,"cells":557},{"EARLY_PHASE1":558,"PHASE1":560,"PHASE2":562,"PHASE3":564,"PHASE4":566,"NA":572},{"trials":559,"activeCount":73},[],{"trials":561,"activeCount":73},[],{"trials":563,"activeCount":73},[],{"trials":565,"activeCount":73},[],{"trials":567,"activeCount":73},[568],{"nctId":542,"briefTitle":543,"status":278,"phases":569,"primaryCompletion":545,"completion":546,"start":547,"enrollment":548,"conditions":570,"interventions":571},[65],[550,551],[529,553],{"trials":573,"activeCount":73},[],{"intervention":575,"totalTrials":69,"cells":576},"PEG-ascorbate 2L",{"EARLY_PHASE1":577,"PHASE1":579,"PHASE2":581,"PHASE3":583,"PHASE4":595,"NA":597},{"trials":578,"activeCount":73},[],{"trials":580,"activeCount":73},[],{"trials":582,"activeCount":73},[],{"trials":584,"activeCount":73},[585],{"nctId":586,"briefTitle":587,"status":278,"phases":588,"primaryCompletion":589,"completion":589,"start":590,"enrollment":398,"conditions":591,"interventions":593},"NCT02297399","Improvement of Tolerance of Bowel Cleansing Before Colonoscopy in Diabetic Patients",[64],"2016-01-26","2014-12-02",[592,23],"Diabetes Mellitus",[575,594],"PEG 4L",{"trials":596,"activeCount":73},[],{"trials":598,"activeCount":73},[],{"intervention":594,"totalTrials":69,"cells":600},{"EARLY_PHASE1":601,"PHASE1":603,"PHASE2":605,"PHASE3":607,"PHASE4":613,"NA":615},{"trials":602,"activeCount":73},[],{"trials":604,"activeCount":73},[],{"trials":606,"activeCount":73},[],{"trials":608,"activeCount":73},[609],{"nctId":586,"briefTitle":587,"status":278,"phases":610,"primaryCompletion":589,"completion":589,"start":590,"enrollment":398,"conditions":611,"interventions":612},[64],[592,23],[575,594],{"trials":614,"activeCount":73},[],{"trials":616,"activeCount":73},[],{"intervention":618,"totalTrials":69,"cells":619},"Propofol",{"EARLY_PHASE1":620,"PHASE1":622,"PHASE2":624,"PHASE3":638,"PHASE4":640,"NA":642},{"trials":621,"activeCount":73},[],{"trials":623,"activeCount":73},[],{"trials":625,"activeCount":73},[626],{"nctId":627,"briefTitle":628,"status":278,"phases":629,"primaryCompletion":630,"completion":631,"start":632,"enrollment":633,"conditions":634,"interventions":636},"NCT03928366","Synchronous Effect of Anesthetics on fMRI, EEG and Clinical Responses",[62,63],"2019-01-09","2021-06-30","2017-06-13",30,[635],"Sedative Overdose",[618,637],"Remifentanil",{"trials":639,"activeCount":73},[],{"trials":641,"activeCount":73},[],{"trials":643,"activeCount":73},[],{"intervention":637,"totalTrials":69,"cells":645},{"EARLY_PHASE1":646,"PHASE1":648,"PHASE2":650,"PHASE3":656,"PHASE4":658,"NA":660},{"trials":647,"activeCount":73},[],{"trials":649,"activeCount":73},[],{"trials":651,"activeCount":73},[652],{"nctId":627,"briefTitle":628,"status":278,"phases":653,"primaryCompletion":630,"completion":631,"start":632,"enrollment":633,"conditions":654,"interventions":655},[62,63],[635],[618,637],{"trials":657,"activeCount":73},[],{"trials":659,"activeCount":73},[],{"trials":661,"activeCount":73},[],{"intervention":663,"totalTrials":664,"cells":665},"Mephedrone",2,{"EARLY_PHASE1":666,"PHASE1":668,"PHASE2":691,"PHASE3":693,"PHASE4":695,"NA":697},{"trials":667,"activeCount":73},[],{"trials":669,"activeCount":73},[670,681],{"nctId":671,"briefTitle":672,"status":278,"phases":673,"primaryCompletion":674,"completion":674,"start":675,"enrollment":676,"conditions":677,"interventions":679},"NCT02232789","Abuse Liability and Human Pharmacology of Mephedrone",[62],"2014-12","2014-09",12,[678],"Amphetamine-Related Disorders",[663,680],"3,4-methylenedioxymethamphetamine",{"nctId":682,"briefTitle":683,"status":278,"phases":684,"primaryCompletion":685,"completion":685,"start":674,"enrollment":676,"conditions":686,"interventions":688},"NCT02294266","Mephedrone and Alcohol Interactions in Humans",[62],"2015-03",[678,687],"Alcohol-Related Disorders",[689,663,690],"Mephedrone and alcohol","Alcohol",{"trials":692,"activeCount":73},[],{"trials":694,"activeCount":73},[],{"trials":696,"activeCount":73},[],{"trials":698,"activeCount":73},[],{"intervention":700,"totalTrials":69,"cells":701},"Intravenous naloxone",{"EARLY_PHASE1":702,"PHASE1":704,"PHASE2":716,"PHASE3":718,"PHASE4":720,"NA":722},{"trials":703,"activeCount":73},[],{"trials":705,"activeCount":73},[706],{"nctId":707,"briefTitle":708,"status":278,"phases":709,"primaryCompletion":710,"completion":711,"start":712,"enrollment":21,"conditions":713,"interventions":714},"NCT06306391","Pharmacokinetics of Intravenous and Intranasal Formulations of Naloxone in Healthy Volunteers.",[62],"2024-05-13","2024-09-02","2024-03-05",[18],[700,715],"Intranasal naloxone",{"trials":717,"activeCount":73},[],{"trials":719,"activeCount":73},[],{"trials":721,"activeCount":73},[],{"trials":723,"activeCount":73},[],{"intervention":715,"totalTrials":69,"cells":725},{"EARLY_PHASE1":726,"PHASE1":728,"PHASE2":734,"PHASE3":736,"PHASE4":738,"NA":740},{"trials":727,"activeCount":73},[],{"trials":729,"activeCount":73},[730],{"nctId":707,"briefTitle":708,"status":278,"phases":731,"primaryCompletion":710,"completion":711,"start":712,"enrollment":21,"conditions":732,"interventions":733},[62],[18],[700,715],{"trials":735,"activeCount":73},[],{"trials":737,"activeCount":73},[],{"trials":739,"activeCount":73},[],{"trials":741,"activeCount":73},[],{"intervention":743,"totalTrials":69,"cells":744},"Hydrochlorothiazide",{"EARLY_PHASE1":745,"PHASE1":747,"PHASE2":757,"PHASE3":759,"PHASE4":761,"NA":763},{"trials":746,"activeCount":73},[],{"trials":748,"activeCount":73},[749],{"nctId":750,"briefTitle":751,"status":278,"phases":752,"primaryCompletion":753,"completion":753,"start":754,"enrollment":31,"conditions":755,"interventions":756},"NCT04197622","Generation of Biological Samples Positive to Hydrochlorothiazide for Anti-doping Control",[62],"2019-03-21","2019-03-05",[15],[743],{"trials":758,"activeCount":73},[],{"trials":760,"activeCount":73},[],{"trials":762,"activeCount":73},[],{"trials":764,"activeCount":73},[],{"intervention":766,"totalTrials":69,"cells":767},"Nicotine",{"EARLY_PHASE1":768,"PHASE1":770,"PHASE2":780,"PHASE3":782,"PHASE4":784,"NA":786},{"trials":769,"activeCount":73},[],{"trials":771,"activeCount":73},[772],{"nctId":773,"briefTitle":774,"status":278,"phases":775,"primaryCompletion":776,"completion":674,"start":421,"enrollment":676,"conditions":777,"interventions":779},"NCT02511704","Pharmacokinetics and Acute Effects of Multiple Dose of Nicotine: Electronic Cigarette and Cigarette",[62],"2014-11",[778],"Nicotine Use Disorder",[766,766],{"trials":781,"activeCount":73},[],{"trials":783,"activeCount":73},[],{"trials":785,"activeCount":73},[],{"trials":787,"activeCount":73},[],{"intervention":789,"totalTrials":69,"cells":790},"Tramadol.",{"EARLY_PHASE1":791,"PHASE1":793,"PHASE2":805,"PHASE3":807,"PHASE4":809,"NA":811},{"trials":792,"activeCount":73},[],{"trials":794,"activeCount":73},[795],{"nctId":796,"briefTitle":797,"status":278,"phases":798,"primaryCompletion":799,"completion":800,"start":801,"enrollment":802,"conditions":803,"interventions":804},"NCT05925686","Tramadol to Improve Its Detection in Biological Matrices in Anti-doping Controls",[62],"2023-10-11","2023-10-17","2023-06-01",25,[18],[789],{"trials":806,"activeCount":73},[],{"trials":808,"activeCount":73},[],{"trials":810,"activeCount":73},[],{"trials":812,"activeCount":73},[],{"intervention":814,"totalTrials":69,"cells":815},"Triptorelin",{"EARLY_PHASE1":816,"PHASE1":818,"PHASE2":828,"PHASE3":830,"PHASE4":832,"NA":834},{"trials":817,"activeCount":73},[],{"trials":819,"activeCount":73},[820],{"nctId":821,"briefTitle":822,"status":278,"phases":823,"primaryCompletion":824,"completion":824,"start":825,"enrollment":664,"conditions":826,"interventions":827},"NCT04189900","Generation of Biological Samples Positive to Triptorelin for Anti-doping Control",[62],"2019-05-15","2019-04-26",[15],[814],{"trials":829,"activeCount":73},[],{"trials":831,"activeCount":73},[],{"trials":833,"activeCount":73},[],{"trials":835,"activeCount":73},[],{"intervention":837,"totalTrials":69,"cells":838},"Somatropin",{"EARLY_PHASE1":839,"PHASE1":841,"PHASE2":852,"PHASE3":854,"PHASE4":856,"NA":858},{"trials":840,"activeCount":73},[],{"trials":842,"activeCount":73},[843],{"nctId":844,"briefTitle":845,"status":278,"phases":846,"primaryCompletion":847,"completion":847,"start":848,"enrollment":849,"conditions":850,"interventions":851},"NCT04042428","Generation of Biological Samples Positive to Somatropin for Anti-doping Control",[62],"2020-01-08","2019-10-25",6,[15],[837],{"trials":853,"activeCount":73},[],{"trials":855,"activeCount":73},[],{"trials":857,"activeCount":73},[],{"trials":859,"activeCount":73},[],{"intervention":861,"totalTrials":69,"cells":862},"EPOETIN ALFA",{"EARLY_PHASE1":863,"PHASE1":865,"PHASE2":876,"PHASE3":878,"PHASE4":880,"NA":882},{"trials":864,"activeCount":73},[],{"trials":866,"activeCount":73},[867],{"nctId":868,"briefTitle":869,"status":278,"phases":870,"primaryCompletion":871,"completion":281,"start":872,"enrollment":664,"conditions":873,"interventions":875},"NCT02920372","Generation of Positive Biological Samples to Epoetin for Doping Control.",[62],"2017-01-17","2016-11-30",[874],"There Are no Conditions Under Study. Healthy Volunteers",[861],{"trials":877,"activeCount":73},[],{"trials":879,"activeCount":73},[],{"trials":881,"activeCount":73},[],{"trials":883,"activeCount":73},[],{"intervention":885,"totalTrials":69,"cells":886},"Methylprednisone",{"EARLY_PHASE1":887,"PHASE1":889,"PHASE2":902,"PHASE3":904,"PHASE4":906,"NA":908},{"trials":888,"activeCount":73},[],{"trials":890,"activeCount":73},[891],{"nctId":892,"briefTitle":893,"status":515,"phases":894,"primaryCompletion":895,"completion":895,"start":896,"enrollment":897,"conditions":898,"interventions":899},"NCT04791345","Study of the Excretion of Orally Administered Corticosteroids for the Improval of the Detection of Said Substances in Anti-doping Controls",[62],"2022-02-26","2021-02-26",50,[15],[885,885,900,901,901],"Deflazacort","Dexamethasone",{"trials":903,"activeCount":73},[],{"trials":905,"activeCount":73},[],{"trials":907,"activeCount":73},[],{"trials":909,"activeCount":73},[],{"intervention":900,"totalTrials":69,"cells":911},{"EARLY_PHASE1":912,"PHASE1":914,"PHASE2":920,"PHASE3":922,"PHASE4":924,"NA":926},{"trials":913,"activeCount":73},[],{"trials":915,"activeCount":73},[916],{"nctId":892,"briefTitle":893,"status":515,"phases":917,"primaryCompletion":895,"completion":895,"start":896,"enrollment":897,"conditions":918,"interventions":919},[62],[15],[885,885,900,901,901],{"trials":921,"activeCount":73},[],{"trials":923,"activeCount":73},[],{"trials":925,"activeCount":73},[],{"trials":927,"activeCount":73},[],{"intervention":901,"totalTrials":69,"cells":929},{"EARLY_PHASE1":930,"PHASE1":932,"PHASE2":938,"PHASE3":940,"PHASE4":942,"NA":944},{"trials":931,"activeCount":73},[],{"trials":933,"activeCount":73},[934],{"nctId":892,"briefTitle":893,"status":515,"phases":935,"primaryCompletion":895,"completion":895,"start":896,"enrollment":897,"conditions":936,"interventions":937},[62],[15],[885,885,900,901,901],{"trials":939,"activeCount":73},[],{"trials":941,"activeCount":73},[],{"trials":943,"activeCount":73},[],{"trials":945,"activeCount":73},[],{"intervention":947,"totalTrials":69,"cells":948},"Oxycodone IN",{"EARLY_PHASE1":949,"PHASE1":951,"PHASE2":963,"PHASE3":965,"PHASE4":967,"NA":969},{"trials":950,"activeCount":73},[],{"trials":952,"activeCount":73},[953],{"nctId":954,"briefTitle":955,"status":278,"phases":956,"primaryCompletion":957,"completion":957,"start":958,"enrollment":21,"conditions":959,"interventions":961},"NCT07223450","A Study on Oral and Intranasal Forms of Oxycodone in Healthy Volunteers Using Pharmacokinetic Modeling",[62],"2025-10-07","2025-06-12",[960,15],"Physiologically Based Pharmacokinetic",[947,962],"oxycodone",{"trials":964,"activeCount":73},[],{"trials":966,"activeCount":73},[],{"trials":968,"activeCount":73},[],{"trials":970,"activeCount":73},[],{"intervention":962,"totalTrials":69,"cells":972},{"EARLY_PHASE1":973,"PHASE1":975,"PHASE2":981,"PHASE3":983,"PHASE4":985,"NA":987},{"trials":974,"activeCount":73},[],{"trials":976,"activeCount":73},[977],{"nctId":954,"briefTitle":955,"status":278,"phases":978,"primaryCompletion":957,"completion":957,"start":958,"enrollment":21,"conditions":979,"interventions":980},[62],[960,15],[947,962],{"trials":982,"activeCount":73},[],{"trials":984,"activeCount":73},[],{"trials":986,"activeCount":73},[],{"trials":988,"activeCount":73},[],{"intervention":990,"totalTrials":69,"cells":991},"Cannabis Sativa",{"EARLY_PHASE1":992,"PHASE1":994,"PHASE2":1006,"PHASE3":1008,"PHASE4":1010,"NA":1012},{"trials":993,"activeCount":73},[],{"trials":995,"activeCount":73},[996],{"nctId":997,"briefTitle":998,"status":489,"phases":999,"primaryCompletion":1000,"completion":1000,"start":1001,"enrollment":1002,"conditions":1003,"interventions":1004},"NCT04316598","Cannabis Effects on Electroencephalography",[62],"2020-07-09","2020-03-03",16,[15],[990,1005],"Cannabis placebo",{"trials":1007,"activeCount":73},[],{"trials":1009,"activeCount":73},[],{"trials":1011,"activeCount":73},[],{"trials":1013,"activeCount":73},[],{"intervention":1005,"totalTrials":69,"cells":1015},{"EARLY_PHASE1":1016,"PHASE1":1018,"PHASE2":1024,"PHASE3":1026,"PHASE4":1028,"NA":1030},{"trials":1017,"activeCount":73},[],{"trials":1019,"activeCount":73},[1020],{"nctId":997,"briefTitle":998,"status":489,"phases":1021,"primaryCompletion":1000,"completion":1000,"start":1001,"enrollment":1002,"conditions":1022,"interventions":1023},[62],[15],[990,1005],{"trials":1025,"activeCount":73},[],{"trials":1027,"activeCount":73},[],{"trials":1029,"activeCount":73},[],{"trials":1031,"activeCount":73},[],{"intervention":1033,"totalTrials":69,"cells":1034},"Zolmitriptan intranasal.",{"EARLY_PHASE1":1035,"PHASE1":1037,"PHASE2":1049,"PHASE3":1051,"PHASE4":1053,"NA":1055},{"trials":1036,"activeCount":73},[],{"trials":1038,"activeCount":73},[1039],{"nctId":1040,"briefTitle":1041,"status":278,"phases":1042,"primaryCompletion":1043,"completion":1044,"start":1045,"enrollment":21,"conditions":1046,"interventions":1047},"NCT06074016","Pharmacokinetics in Oral and Intranasal Formulations of Zolmitriptan.",[62],"2023-09-06","2023-09-29","2023-07-12",[18],[1033,1048],"Zolmitriptan oral.",{"trials":1050,"activeCount":73},[],{"trials":1052,"activeCount":73},[],{"trials":1054,"activeCount":73},[],{"trials":1056,"activeCount":73},[],{"intervention":1048,"totalTrials":69,"cells":1058},{"EARLY_PHASE1":1059,"PHASE1":1061,"PHASE2":1067,"PHASE3":1069,"PHASE4":1071,"NA":1073},{"trials":1060,"activeCount":73},[],{"trials":1062,"activeCount":73},[1063],{"nctId":1040,"briefTitle":1041,"status":278,"phases":1064,"primaryCompletion":1043,"completion":1044,"start":1045,"enrollment":21,"conditions":1065,"interventions":1066},[62],[18],[1033,1048],{"trials":1068,"activeCount":73},[],{"trials":1070,"activeCount":73},[],{"trials":1072,"activeCount":73},[],{"trials":1074,"activeCount":73},[],{"intervention":1076,"totalTrials":69,"cells":1077},"Fluconazole",{"EARLY_PHASE1":1078,"PHASE1":1080,"PHASE2":1090,"PHASE3":1092,"PHASE4":1094,"NA":1096},{"trials":1079,"activeCount":73},[],{"trials":1081,"activeCount":73},[1082],{"nctId":1083,"briefTitle":1084,"status":278,"phases":1085,"primaryCompletion":1086,"completion":1086,"start":1087,"enrollment":664,"conditions":1088,"interventions":1089},"NCT04201054","Generation of Biological Samples Positive to Fluconazole for Anti-Doping Control",[62],"2019-04-05","2019-03-25",[15],[1076],{"trials":1091,"activeCount":73},[],{"trials":1093,"activeCount":73},[],{"trials":1095,"activeCount":73},[],{"trials":1097,"activeCount":73},[],{"intervention":680,"totalTrials":69,"cells":1099},{"EARLY_PHASE1":1100,"PHASE1":1102,"PHASE2":1108,"PHASE3":1110,"PHASE4":1112,"NA":1114},{"trials":1101,"activeCount":73},[],{"trials":1103,"activeCount":73},[1104],{"nctId":671,"briefTitle":672,"status":278,"phases":1105,"primaryCompletion":674,"completion":674,"start":675,"enrollment":676,"conditions":1106,"interventions":1107},[62],[678],[663,680],{"trials":1109,"activeCount":73},[],{"trials":1111,"activeCount":73},[],{"trials":1113,"activeCount":73},[],{"trials":1115,"activeCount":73},[],{"intervention":689,"totalTrials":69,"cells":1117},{"EARLY_PHASE1":1118,"PHASE1":1120,"PHASE2":1126,"PHASE3":1128,"PHASE4":1130,"NA":1132},{"trials":1119,"activeCount":73},[],{"trials":1121,"activeCount":73},[1122],{"nctId":682,"briefTitle":683,"status":278,"phases":1123,"primaryCompletion":685,"completion":685,"start":674,"enrollment":676,"conditions":1124,"interventions":1125},[62],[678,687],[689,663,690],{"trials":1127,"activeCount":73},[],{"trials":1129,"activeCount":73},[],{"trials":1131,"activeCount":73},[],{"trials":1133,"activeCount":73},[],{"intervention":690,"totalTrials":69,"cells":1135},{"EARLY_PHASE1":1136,"PHASE1":1138,"PHASE2":1144,"PHASE3":1146,"PHASE4":1148,"NA":1150},{"trials":1137,"activeCount":73},[],{"trials":1139,"activeCount":73},[1140],{"nctId":682,"briefTitle":683,"status":278,"phases":1141,"primaryCompletion":685,"completion":685,"start":674,"enrollment":676,"conditions":1142,"interventions":1143},[62],[678,687],[689,663,690],{"trials":1145,"activeCount":73},[],{"trials":1147,"activeCount":73},[],{"trials":1149,"activeCount":73},[],{"trials":1151,"activeCount":73},[],{"intervention":1153,"totalTrials":69,"cells":1154},"LEUPRORELIN ACETATE",{"EARLY_PHASE1":1155,"PHASE1":1157,"PHASE2":1167,"PHASE3":1169,"PHASE4":1171,"NA":1173},{"trials":1156,"activeCount":73},[],{"trials":1158,"activeCount":73},[1159],{"nctId":1160,"briefTitle":1161,"status":278,"phases":1162,"primaryCompletion":1163,"completion":281,"start":1164,"enrollment":24,"conditions":1165,"interventions":1166},"NCT02920359","Generation of Positive Biological Samples to Leuprolide Acetate for Doping Control",[62],"2016-12-13","2016-11-17",[874],[1153],{"trials":1168,"activeCount":73},[],{"trials":1170,"activeCount":73},[],{"trials":1172,"activeCount":73},[],{"trials":1174,"activeCount":73},[],{"intervention":1176,"totalTrials":69,"cells":1177},"Testosterone gel",{"EARLY_PHASE1":1178,"PHASE1":1180,"PHASE2":1193,"PHASE3":1195,"PHASE4":1197,"NA":1199},{"trials":1179,"activeCount":73},[],{"trials":1181,"activeCount":73},[1182],{"nctId":1183,"briefTitle":1184,"status":278,"phases":1185,"primaryCompletion":1186,"completion":1186,"start":1187,"enrollment":9,"conditions":1188,"interventions":1189},"NCT04166786","Steroid Profile: Differentiating Testosterone Administration From (Simultaneous) Ethanol Consumption",[62],"2019-09-26","2019-05-06",[15],[1176,1190,1191,1192],"Ethanol Solution","Testosterone placebo","Ethanol placebo",{"trials":1194,"activeCount":73},[],{"trials":1196,"activeCount":73},[],{"trials":1198,"activeCount":73},[],{"trials":1200,"activeCount":73},[],{"intervention":1190,"totalTrials":69,"cells":1202},{"EARLY_PHASE1":1203,"PHASE1":1205,"PHASE2":1211,"PHASE3":1213,"PHASE4":1215,"NA":1217},{"trials":1204,"activeCount":73},[],{"trials":1206,"activeCount":73},[1207],{"nctId":1183,"briefTitle":1184,"status":278,"phases":1208,"primaryCompletion":1186,"completion":1186,"start":1187,"enrollment":9,"conditions":1209,"interventions":1210},[62],[15],[1176,1190,1191,1192],{"trials":1212,"activeCount":73},[],{"trials":1214,"activeCount":73},[],{"trials":1216,"activeCount":73},[],{"trials":1218,"activeCount":73},[],{"intervention":1191,"totalTrials":69,"cells":1220},{"EARLY_PHASE1":1221,"PHASE1":1223,"PHASE2":1229,"PHASE3":1231,"PHASE4":1233,"NA":1235},{"trials":1222,"activeCount":73},[],{"trials":1224,"activeCount":73},[1225],{"nctId":1183,"briefTitle":1184,"status":278,"phases":1226,"primaryCompletion":1186,"completion":1186,"start":1187,"enrollment":9,"conditions":1227,"interventions":1228},[62],[15],[1176,1190,1191,1192],{"trials":1230,"activeCount":73},[],{"trials":1232,"activeCount":73},[],{"trials":1234,"activeCount":73},[],{"trials":1236,"activeCount":73},[],{"intervention":1192,"totalTrials":69,"cells":1238},{"EARLY_PHASE1":1239,"PHASE1":1241,"PHASE2":1247,"PHASE3":1249,"PHASE4":1251,"NA":1253},{"trials":1240,"activeCount":73},[],{"trials":1242,"activeCount":73},[1243],{"nctId":1183,"briefTitle":1184,"status":278,"phases":1244,"primaryCompletion":1186,"completion":1186,"start":1187,"enrollment":9,"conditions":1245,"interventions":1246},[62],[15],[1176,1190,1191,1192],{"trials":1248,"activeCount":73},[],{"trials":1250,"activeCount":73},[],{"trials":1252,"activeCount":73},[],{"trials":1254,"activeCount":73},[],{"intervention":1256,"totalTrials":69,"cells":1257},"Bupropion",{"EARLY_PHASE1":1258,"PHASE1":1260,"PHASE2":1274,"PHASE3":1276,"PHASE4":1278,"NA":1280},{"trials":1259,"activeCount":73},[],{"trials":1261,"activeCount":73},[1262],{"nctId":1263,"briefTitle":1264,"status":278,"phases":1265,"primaryCompletion":1266,"completion":1266,"start":1267,"enrollment":11,"conditions":1268,"interventions":1269},"NCT04757532","Study of Exposure to Substances Prohibited by the World Anti-Doping Agency in Healthy Volunteers.",[62],"2021-03-10","2020-12-03",[15],[1256,1270,1271,1272,1273],"Anastrozole","Testosterone cyclopentylpropionate","Danazol","Chlorthalidone",{"trials":1275,"activeCount":73},[],{"trials":1277,"activeCount":73},[],{"trials":1279,"activeCount":73},[],{"trials":1281,"activeCount":73},[],{"intervention":1270,"totalTrials":69,"cells":1283},{"EARLY_PHASE1":1284,"PHASE1":1286,"PHASE2":1292,"PHASE3":1294,"PHASE4":1296,"NA":1298},{"trials":1285,"activeCount":73},[],{"trials":1287,"activeCount":73},[1288],{"nctId":1263,"briefTitle":1264,"status":278,"phases":1289,"primaryCompletion":1266,"completion":1266,"start":1267,"enrollment":11,"conditions":1290,"interventions":1291},[62],[15],[1256,1270,1271,1272,1273],{"trials":1293,"activeCount":73},[],{"trials":1295,"activeCount":73},[],{"trials":1297,"activeCount":73},[],{"trials":1299,"activeCount":73},[],{"intervention":1271,"totalTrials":69,"cells":1301},{"EARLY_PHASE1":1302,"PHASE1":1304,"PHASE2":1310,"PHASE3":1312,"PHASE4":1314,"NA":1316},{"trials":1303,"activeCount":73},[],{"trials":1305,"activeCount":73},[1306],{"nctId":1263,"briefTitle":1264,"status":278,"phases":1307,"primaryCompletion":1266,"completion":1266,"start":1267,"enrollment":11,"conditions":1308,"interventions":1309},[62],[15],[1256,1270,1271,1272,1273],{"trials":1311,"activeCount":73},[],{"trials":1313,"activeCount":73},[],{"trials":1315,"activeCount":73},[],{"trials":1317,"activeCount":73},[],{"intervention":1272,"totalTrials":69,"cells":1319},{"EARLY_PHASE1":1320,"PHASE1":1322,"PHASE2":1328,"PHASE3":1330,"PHASE4":1332,"NA":1334},{"trials":1321,"activeCount":73},[],{"trials":1323,"activeCount":73},[1324],{"nctId":1263,"briefTitle":1264,"status":278,"phases":1325,"primaryCompletion":1266,"completion":1266,"start":1267,"enrollment":11,"conditions":1326,"interventions":1327},[62],[15],[1256,1270,1271,1272,1273],{"trials":1329,"activeCount":73},[],{"trials":1331,"activeCount":73},[],{"trials":1333,"activeCount":73},[],{"trials":1335,"activeCount":73},[],{"intervention":1273,"totalTrials":69,"cells":1337},{"EARLY_PHASE1":1338,"PHASE1":1340,"PHASE2":1346,"PHASE3":1348,"PHASE4":1350,"NA":1352},{"trials":1339,"activeCount":73},[],{"trials":1341,"activeCount":73},[1342],{"nctId":1263,"briefTitle":1264,"status":278,"phases":1343,"primaryCompletion":1266,"completion":1266,"start":1267,"enrollment":11,"conditions":1344,"interventions":1345},[62],[15],[1256,1270,1271,1272,1273],{"trials":1347,"activeCount":73},[],{"trials":1349,"activeCount":73},[],{"trials":1351,"activeCount":73},[],{"trials":1353,"activeCount":73},[],{"intervention":1355,"totalTrials":69,"cells":1356},"MDMA",{"EARLY_PHASE1":1357,"PHASE1":1359,"PHASE2":1372,"PHASE3":1374,"PHASE4":1376,"NA":1378},{"trials":1358,"activeCount":73},[],{"trials":1360,"activeCount":73},[1361],{"nctId":1362,"briefTitle":1363,"status":278,"phases":1364,"primaryCompletion":1365,"completion":1366,"start":1367,"enrollment":8,"conditions":1368,"interventions":1371},"NCT01447472","-Methylenedioxymethamphetamine (MDMA, Ecstasy) Induced Changes in Drug Metabolism: Gender and Genetic Polymorphisms",[62],"2009-05","2011-05","2003-05",[1369,1370],"Metabolism","Interaction",[1355],{"trials":1373,"activeCount":73},[],{"trials":1375,"activeCount":73},[],{"trials":1377,"activeCount":73},[],{"trials":1379,"activeCount":73},[],{"intervention":1381,"totalTrials":69,"cells":1382},"Budesonide",{"EARLY_PHASE1":1383,"PHASE1":1385,"PHASE2":1396,"PHASE3":1398,"PHASE4":1400,"NA":1402},{"trials":1384,"activeCount":73},[],{"trials":1386,"activeCount":73},[1387],{"nctId":1388,"briefTitle":1389,"status":278,"phases":1390,"primaryCompletion":1391,"completion":1392,"start":1393,"enrollment":9,"conditions":1394,"interventions":1395},"NCT03537326","Study to Detect Oral Administration of Budesonide in Women.",[62],"2018-07-01","2018-09-10","2018-05-22",[18],[1381],{"trials":1397,"activeCount":73},[],{"trials":1399,"activeCount":73},[],{"trials":1401,"activeCount":73},[],{"trials":1403,"activeCount":73},[],{"intervention":1405,"totalTrials":69,"cells":1406},"Salmeterol Xinafoate",{"EARLY_PHASE1":1407,"PHASE1":1409,"PHASE2":1419,"PHASE3":1421,"PHASE4":1423,"NA":1425},{"trials":1408,"activeCount":73},[],{"trials":1410,"activeCount":73},[1411],{"nctId":1412,"briefTitle":1413,"status":278,"phases":1414,"primaryCompletion":1415,"completion":1415,"start":1416,"enrollment":9,"conditions":1417,"interventions":1418},"NCT04195867","Generation of Biological Samples Positive to Salmeterol for Anti-Doping Control",[62],"2019-01-08","2018-11-20",[15],[1405],{"trials":1420,"activeCount":73},[],{"trials":1422,"activeCount":73},[],{"trials":1424,"activeCount":73},[],{"trials":1426,"activeCount":73},[],{"intervention":1428,"totalTrials":69,"cells":1429},"Testosterone",{"EARLY_PHASE1":1430,"PHASE1":1432,"PHASE2":1442,"PHASE3":1444,"PHASE4":1446,"NA":1448},{"trials":1431,"activeCount":73},[],{"trials":1433,"activeCount":73},[1434],{"nctId":1435,"briefTitle":1436,"status":278,"phases":1437,"primaryCompletion":1438,"completion":1438,"start":1439,"enrollment":9,"conditions":1440,"interventions":1441},"NCT04207684","Generation of Biological Samples Positive to Testosterone for Anti-doping Control",[62],"2020-02-26","2020-02-04",[15],[1428],{"trials":1443,"activeCount":73},[],{"trials":1445,"activeCount":73},[],{"trials":1447,"activeCount":73},[],{"trials":1449,"activeCount":73},[],{"intervention":1451,"totalTrials":69,"cells":1452},"Hydromorphone Hydrochloride",{"EARLY_PHASE1":1453,"PHASE1":1455,"PHASE2":1465,"PHASE3":1467,"PHASE4":1469,"NA":1471},{"trials":1454,"activeCount":73},[],{"trials":1456,"activeCount":73},[1457],{"nctId":1458,"briefTitle":1459,"status":278,"phases":1460,"primaryCompletion":1461,"completion":1461,"start":1462,"enrollment":664,"conditions":1463,"interventions":1464},"NCT04081376","Generation of Biological Samples Positive to Hydromorphone for Anti-doping Control",[62],"2019-12-18","2019-11-20",[15],[1451],{"trials":1466,"activeCount":73},[],{"trials":1468,"activeCount":73},[],{"trials":1470,"activeCount":73},[],{"trials":1472,"activeCount":73},[],{"intervention":1474,"totalTrials":69,"cells":1475},"Acetylsalicylic acid",{"EARLY_PHASE1":1476,"PHASE1":1478,"PHASE2":1480,"PHASE3":1482,"PHASE4":1484,"NA":1486},{"trials":1477,"activeCount":73},[],{"trials":1479,"activeCount":73},[],{"trials":1481,"activeCount":73},[],{"trials":1483,"activeCount":73},[],{"trials":1485,"activeCount":73},[],{"trials":1487,"activeCount":73},[1488],{"nctId":1489,"briefTitle":1490,"status":278,"phases":1491,"primaryCompletion":1492,"completion":1493,"start":1494,"enrollment":1495,"conditions":1496,"interventions":1498},"NCT03133260","A Project to Improve the Diagnosis and Prognosis of Myocardial Injury Associated to Non Cardiac Surgery",[],"2019-04-30","2021-10-15","2017-05-02",800,[1497],"Myocardium; Injury",[1474,1499],"Statin",{"intervention":1499,"totalTrials":69,"cells":1501},{"EARLY_PHASE1":1502,"PHASE1":1504,"PHASE2":1506,"PHASE3":1508,"PHASE4":1510,"NA":1512},{"trials":1503,"activeCount":73},[],{"trials":1505,"activeCount":73},[],{"trials":1507,"activeCount":73},[],{"trials":1509,"activeCount":73},[],{"trials":1511,"activeCount":73},[],{"trials":1513,"activeCount":73},[1514],{"nctId":1489,"briefTitle":1490,"status":278,"phases":1515,"primaryCompletion":1492,"completion":1493,"start":1494,"enrollment":1495,"conditions":1516,"interventions":1517},[],[1497],[1474,1499],{"intervention":1519,"totalTrials":69,"cells":1520},"Chemoradiation treatment regimen and maintenance",{"EARLY_PHASE1":1521,"PHASE1":1523,"PHASE2":1525,"PHASE3":1527,"PHASE4":1529,"NA":1531},{"trials":1522,"activeCount":73},[],{"trials":1524,"activeCount":73},[],{"trials":1526,"activeCount":73},[],{"trials":1528,"activeCount":73},[],{"trials":1530,"activeCount":73},[],{"trials":1532,"activeCount":73},[1533],{"nctId":1534,"briefTitle":1535,"status":515,"phases":1536,"primaryCompletion":1537,"completion":1537,"start":1538,"enrollment":1539,"conditions":1540,"interventions":1543},"NCT05641870","Molecular Profiling and Dynamic Changes of ctDNA in Unresectable Locally Advanced NSCLC",[],"2023-12","2021-02-01",80,[30,1541,1542],"Stage III Lung Cancer","Unresectable Lung Carcinoma",[1519],{"intervention":1545,"totalTrials":69,"cells":1546},"Treatment as usual",{"EARLY_PHASE1":1547,"PHASE1":1549,"PHASE2":1551,"PHASE3":1553,"PHASE4":1555,"NA":1557},{"trials":1548,"activeCount":73},[],{"trials":1550,"activeCount":73},[],{"trials":1552,"activeCount":73},[],{"trials":1554,"activeCount":73},[],{"trials":1556,"activeCount":73},[],{"trials":1558,"activeCount":73},[1559],{"nctId":1560,"briefTitle":1561,"status":515,"phases":1562,"primaryCompletion":1563,"completion":1564,"start":1565,"enrollment":1566,"conditions":1567,"interventions":1569},"NCT03991377","A Rater-blinded RCT to Compare Effectiveness of EMDR vs TAU in Patients With First Episode Psychosis and History of Psychological Trauma",[66],"2024-11-30","2024-12-31","2019-04-25",71,[1568,20],"Psychotic Episode",[1545],{"intervention":1571,"totalTrials":69,"cells":1572},"Cefazolin",{"EARLY_PHASE1":1573,"PHASE1":1575,"PHASE2":1577,"PHASE3":1579,"PHASE4":1581,"NA":1583},{"trials":1574,"activeCount":73},[],{"trials":1576,"activeCount":73},[],{"trials":1578,"activeCount":73},[],{"trials":1580,"activeCount":73},[],{"trials":1582,"activeCount":73},[],{"trials":1584,"activeCount":73},[1585],{"nctId":1586,"briefTitle":1587,"status":278,"phases":1588,"primaryCompletion":674,"completion":1589,"start":1590,"enrollment":1591,"conditions":1592,"interventions":1594},"NCT02413034","The Influence of Antibiotic Prophylaxis on Intraoperative Prosthetic Joint Infection Cultures",[66],"2015-01","2013-11",28,[1593],"Prosthetic Joint Infection",[1571],{"intervention":1596,"totalTrials":69,"cells":1597},"Colostrum",{"EARLY_PHASE1":1598,"PHASE1":1600,"PHASE2":1602,"PHASE3":1604,"PHASE4":1606,"NA":1608},{"trials":1599,"activeCount":73},[],{"trials":1601,"activeCount":73},[],{"trials":1603,"activeCount":73},[],{"trials":1605,"activeCount":73},[],{"trials":1607,"activeCount":73},[],{"trials":1609,"activeCount":73},[1610],{"nctId":1611,"briefTitle":1612,"status":278,"phases":1613,"primaryCompletion":1614,"completion":1615,"start":1616,"enrollment":1617,"conditions":1618,"interventions":1621},"NCT06869902","Use of Inhaled Colostrum to Control Pain in Neonatal Frenotomy and Comparison to Inhaled Lavender Essential Oil",[66],"2024-06-14","2024-06-30","2023-09-18",142,[1619,33,1620],"Pain","Neonate",[1596],{"intervention":1623,"totalTrials":69,"cells":1624},"Treatment with aldactone",{"EARLY_PHASE1":1625,"PHASE1":1627,"PHASE2":1629,"PHASE3":1631,"PHASE4":1633,"NA":1635},{"trials":1626,"activeCount":73},[],{"trials":1628,"activeCount":73},[],{"trials":1630,"activeCount":73},[],{"trials":1632,"activeCount":73},[],{"trials":1634,"activeCount":73},[],{"trials":1636,"activeCount":73},[1637],{"nctId":1638,"briefTitle":1639,"status":278,"phases":1640,"primaryCompletion":1641,"completion":1641,"start":1642,"enrollment":1643,"conditions":1644,"interventions":1646},"NCT02039492","Sympathetic Renal Denervation Versus Increment of Pharmacological Treatment in Resistant Arterial Hypertension.",[66],"2015-12","2012-09",38,[1645],"Resistant Arterial Hypertension",[1623],{"intervention":1648,"totalTrials":69,"cells":1649},"Pegylated interferon alfa-2a + Ribavirin",{"EARLY_PHASE1":1650,"PHASE1":1652,"PHASE2":1654,"PHASE3":1656,"PHASE4":1658,"NA":1660},{"trials":1651,"activeCount":73},[],{"trials":1653,"activeCount":73},[],{"trials":1655,"activeCount":73},[],{"trials":1657,"activeCount":73},[],{"trials":1659,"activeCount":73},[],{"trials":1661,"activeCount":73},[1662],{"nctId":1663,"briefTitle":1664,"status":278,"phases":1665,"primaryCompletion":1666,"completion":1667,"start":1668,"enrollment":1669,"conditions":1670,"interventions":1673},"NCT02758509","Impact of Antiviral Therapy on Gastroesophageal Varices.",[],"2017-06-15","2017-10-15","2010-01-01",237,[1671,1672],"Chronic Hepatitis C","Cirrhosis",[1648,1674,1675,1676,1677,1678,1679],"Pegylated interferon alfa-2a + Ribavirin + Boceprevir","Pegylated interferon alfa-2a + Ribavirin +Telaprevir","Ledipasvir\u002FSofosbuvir","Ombitasvir\u002Fparitaprevir\u002Fritonavir+Dasabuvir","Daclatasvir+Sofosbuvir","Simeprevir+Sofosbuvir",{"intervention":1674,"totalTrials":69,"cells":1681},{"EARLY_PHASE1":1682,"PHASE1":1684,"PHASE2":1686,"PHASE3":1688,"PHASE4":1690,"NA":1692},{"trials":1683,"activeCount":73},[],{"trials":1685,"activeCount":73},[],{"trials":1687,"activeCount":73},[],{"trials":1689,"activeCount":73},[],{"trials":1691,"activeCount":73},[],{"trials":1693,"activeCount":73},[1694],{"nctId":1663,"briefTitle":1664,"status":278,"phases":1695,"primaryCompletion":1666,"completion":1667,"start":1668,"enrollment":1669,"conditions":1696,"interventions":1697},[],[1671,1672],[1648,1674,1675,1676,1677,1678,1679],{"intervention":1675,"totalTrials":69,"cells":1699},{"EARLY_PHASE1":1700,"PHASE1":1702,"PHASE2":1704,"PHASE3":1706,"PHASE4":1708,"NA":1710},{"trials":1701,"activeCount":73},[],{"trials":1703,"activeCount":73},[],{"trials":1705,"activeCount":73},[],{"trials":1707,"activeCount":73},[],{"trials":1709,"activeCount":73},[],{"trials":1711,"activeCount":73},[1712],{"nctId":1663,"briefTitle":1664,"status":278,"phases":1713,"primaryCompletion":1666,"completion":1667,"start":1668,"enrollment":1669,"conditions":1714,"interventions":1715},[],[1671,1672],[1648,1674,1675,1676,1677,1678,1679],{"intervention":1676,"totalTrials":69,"cells":1717},{"EARLY_PHASE1":1718,"PHASE1":1720,"PHASE2":1722,"PHASE3":1724,"PHASE4":1726,"NA":1728},{"trials":1719,"activeCount":73},[],{"trials":1721,"activeCount":73},[],{"trials":1723,"activeCount":73},[],{"trials":1725,"activeCount":73},[],{"trials":1727,"activeCount":73},[],{"trials":1729,"activeCount":73},[1730],{"nctId":1663,"briefTitle":1664,"status":278,"phases":1731,"primaryCompletion":1666,"completion":1667,"start":1668,"enrollment":1669,"conditions":1732,"interventions":1733},[],[1671,1672],[1648,1674,1675,1676,1677,1678,1679],{"intervention":1677,"totalTrials":69,"cells":1735},{"EARLY_PHASE1":1736,"PHASE1":1738,"PHASE2":1740,"PHASE3":1742,"PHASE4":1744,"NA":1746},{"trials":1737,"activeCount":73},[],{"trials":1739,"activeCount":73},[],{"trials":1741,"activeCount":73},[],{"trials":1743,"activeCount":73},[],{"trials":1745,"activeCount":73},[],{"trials":1747,"activeCount":73},[1748],{"nctId":1663,"briefTitle":1664,"status":278,"phases":1749,"primaryCompletion":1666,"completion":1667,"start":1668,"enrollment":1669,"conditions":1750,"interventions":1751},[],[1671,1672],[1648,1674,1675,1676,1677,1678,1679],{"intervention":1678,"totalTrials":69,"cells":1753},{"EARLY_PHASE1":1754,"PHASE1":1756,"PHASE2":1758,"PHASE3":1760,"PHASE4":1762,"NA":1764},{"trials":1755,"activeCount":73},[],{"trials":1757,"activeCount":73},[],{"trials":1759,"activeCount":73},[],{"trials":1761,"activeCount":73},[],{"trials":1763,"activeCount":73},[],{"trials":1765,"activeCount":73},[1766],{"nctId":1663,"briefTitle":1664,"status":278,"phases":1767,"primaryCompletion":1666,"completion":1667,"start":1668,"enrollment":1669,"conditions":1768,"interventions":1769},[],[1671,1672],[1648,1674,1675,1676,1677,1678,1679],{"intervention":1679,"totalTrials":69,"cells":1771},{"EARLY_PHASE1":1772,"PHASE1":1774,"PHASE2":1776,"PHASE3":1778,"PHASE4":1780,"NA":1782},{"trials":1773,"activeCount":73},[],{"trials":1775,"activeCount":73},[],{"trials":1777,"activeCount":73},[],{"trials":1779,"activeCount":73},[],{"trials":1781,"activeCount":73},[],{"trials":1783,"activeCount":73},[1784],{"nctId":1663,"briefTitle":1664,"status":278,"phases":1785,"primaryCompletion":1666,"completion":1667,"start":1668,"enrollment":1669,"conditions":1786,"interventions":1787},[],[1671,1672],[1648,1674,1675,1676,1677,1678,1679],{"intervention":1789,"totalTrials":69,"cells":1790},"Oxygen",{"EARLY_PHASE1":1791,"PHASE1":1793,"PHASE2":1795,"PHASE3":1797,"PHASE4":1799,"NA":1801},{"trials":1792,"activeCount":73},[],{"trials":1794,"activeCount":73},[],{"trials":1796,"activeCount":73},[],{"trials":1798,"activeCount":73},[],{"trials":1800,"activeCount":73},[],{"trials":1802,"activeCount":73},[1803],{"nctId":1804,"briefTitle":1805,"status":278,"phases":1806,"primaryCompletion":1807,"completion":1808,"start":1809,"enrollment":1810,"conditions":1811,"interventions":1813},"NCT04564664","High-flow Oxygen Therapy During Exercise in Idiopathic Pulmonary Fibrosis",[66],"2020-12-30","2021-03-30","2019-03-01",10,[1812],"Idiopathic Pulmonary Fibrosis",[1789],{"intervention":1815,"totalTrials":69,"cells":1816},"Vedolizumab",{"EARLY_PHASE1":1817,"PHASE1":1819,"PHASE2":1821,"PHASE3":1823,"PHASE4":1825,"NA":1827},{"trials":1818,"activeCount":73},[],{"trials":1820,"activeCount":73},[],{"trials":1822,"activeCount":73},[],{"trials":1824,"activeCount":73},[],{"trials":1826,"activeCount":73},[],{"trials":1828,"activeCount":73},[1829],{"nctId":1830,"briefTitle":1831,"status":278,"phases":1832,"primaryCompletion":1833,"completion":1833,"start":1834,"enrollment":1835,"conditions":1836,"interventions":1838},"NCT02712866","Early Biomarkers in Circulating α 4β7 + T Cells to Predict Response to Vedolizumab in Inflamatory Bowel Disease Patients.",[],"2019-02","2017-01",24,[1837],"Inflammatory Bowel Disease",[1815]]